Janssen has sued Samsung Bioepis, alleging it violated a settlement agreement by authorizing an unauthorized Stelara® ...

Pharmacy- and manufacturer-neutral approach offers members access to therapeutically equivalent, lower cost alternativesSAN DIEGO--(BUSINESS WIRE)--MedImpact Healthcare Systems, the nation’s largest ...

Samsung Bioepis has allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous ...

Johnson & Johnson filed a lawsuit against Samsung Bioepis for allegedly breaching their agreement over the launch of ...

Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...

Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...

Eli Lilly will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells ...

Samsung Bioepis allegedly entered into an agreement with a third-party health company, allowing it to market its own private ...

Johnson & Johnson said on Monday it had filed a lawsuit against Samsung Bioepis for breaching its contract agreement with the ...

The company's subsidiary has launched the Yesintek biosimilar in the United States. This is one of the first Stelara ...

As biosimilar versions of a big-selling Johnson & Johnson medicine reach the U.S. market, the health care giant accused one ...

Selarsdi is approved by the FDA in several presentations, including 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled ...